Fritextsökning
Innehållstyper
-
Lovande resultat för Lillys fetmapiller – skapar börsvågor
Eli Lillys viktminskningspiller överträffar förväntningarna i en fas III-studie och visar resultat i nivå med injicerbara läkemedel som Ozempic. Nyheten fick ak...
-
A new special edition and a new event in Copenhagen – This is happening at Life Science Sweden 2024
The new year brings new features for the readers of Life Science Sweden.
-
Carl Zeiss Meditec achieves revenue growth and stable operating profit
Further recovery in order entry compared to prior year.
-
USA:s regering skrotar vaccinavtal med Moderna
Trumpadministrationen har avbrutit ett kontrakt som tilldelats Moderna för den sena utvecklingsfasen av ett fågelinfluensavaccin för människor, samt rätten att ...
-
The dock that “thinks” for itself
The world of bulk material handling seems straightforward at first glance: moving, filling, delivering. However, the art of dealing with a variety of different ...
-
Webinar: Can AI replace humans in pharmacovigilance?
The webinar will explore how AI can transform pharmacovigilance by enhancing efficiency, reducing errors, and addressing challenges such as software costs, data security, and regulatory gaps....
-
A tiny animal with great importance
From the mythical Ganges River to the less sacred, but considerably cleaner waters in KI's aquariums in Solna. The little zebrafish has made an unconscious care...
-
The US is leaving the WHO
The newly installed US President, Donald Trump, has issued an executive order for the US to leave the World Health Organization, WHO.
-
Positive EMA Decision for BioArctic's New Drug Candidate
Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).
-
AstraZeneca´s Trixeo approved in the UK using propellant with near-zero Global Warming Potential
AstraZeneca has received approval in the United Kingdom for its inhaled respiratory medicine Trixeo Aerosphere with a new propellant that is reported to reduce ...
-
Wegovy slog Mounjaro i studie om hjärtinfarkt
Under söndagen presenterade Novo Nordisk ny studiedata som pekar på att Wegovy kan minska risken för allvarliga kardiovaskulära händelser mer än Eli Lillys konk...
-
The Crucial Role of Core Imaging Facility Managers
User story from ZEISS and the University of York.
-
Kvinna dog – J&J döms till miljardskadestånd
En jury i Los Angeles har dömt Johnson & Johnson (J&J) att betala motsvarande omkring 9,1 miljarder kronor till familjen till en kvinna som avlidit i mesoteliom...
-
Achieve Efficient, Fast Targeting of Your Sample
Step into the future of imaging technology with VersaXRM 730.
-
How to Assure Quality within R&D Medical Devices
Free webinar on June 3rd, 2025, 9:00 - 9:45 AM CEST and 5:00 - 5:45 PM CEST.
-
ZEISS unveils AI-powered Research Data Platform
Collaboration with Boehringer Ingelheim champions the future of personalized eye care.
-
Reveal the Structures and Functions of Life
Super-resolution microscopes from ZEISS.
-
Icelandic pharmaceutical company Alvotech to list on Nasdaq Stockholm
One of Iceland's largest companies, the pharmaceutical firm Alvotech, has announced its intention to list on Nasdaq Stockholm.
-
Join our measuringhero Jay on the innovation tour
Experience our latest innovation from the Control fair.
-
Rising interest in CRISPR treatments
Treatments using CRISPR technology are emerging as one of the hottest medical trends in the United States – and the FDA is doing its best to promote the development.
-
ZEISS continues to drive digital era forward in ophthalmology
2 million digitally planned cataract cases in the U.S. alone.
-
Automated dispensing of liquids
Have a look at how you can do easier and faster dispensing on the fly adapted to your needs
-
ZEISS introduces the new Smartzoom 100
The future of digital microscopy for efficient optical inspections.
-
The scientist behind Novo Nordisk's obesity success: “I never stopped believing in GLP-1”
It took several years of failures in GLP-1 before Lotte Bjerre Knudsen and her colleagues found the right path – but when they did, it was a true breakthrough. ...
BREAKING